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ABSTRACT 
Tumor growth is dependent on angiogenesis, and cells in tumor tissues produce various 
angiogenic factors to induce neovascularization. Among tumor-derived angiogenic factors, 
members of the vascular endothelial growth factor (VEGF) family are most frequently and 
highly expressed in various solid tumors. VEGF-A, the prototype of VEGF, is the most 
powerful pro-angiogenic factor that binds to VEGF receptor-1 (VEGFR-1, also called FMS-
Related Tyrosine Kinase-1/Flt-1) and VEGFR-2 (also called Kinase Insert Domain 
Receptor/KDR or Fetal Liver Kinase -1/Flk-1). While the VEGFR-2-transduced angiogenic 
signals, pathways, and functions are well characterized, the VEGFR-1-mediated functions are 
poorly understood. The angiogenic functions of placental growth factor (PlGF), which is a 
specific VEGFR-1-binding ligand, remain controversial. The role of VEGF-B in tumor 
angiogenesis is still unclear. In addition, the two other VEGF family members, VEGF-C and 
VEGF-D are the major lymphangiogenic factors that contribute to lymphatic metastasis.  
The work contained in this thesis aimed to study the role of VEGF family members in 
angiogenesis, tumor growth and metastasis. Our work shows that PlGF exhibits a duality in 
modulation of angiogenesis and tumor growth in a VEGF-A-dependent manner. This is noted 
when the tumor cell-derived PlGF sensitizes the tumor to the anti-angiogenic and anti-tumor 
effects of anti-VEGF drugs. We also noted that anti-VEGF treatment induces various 
vascular alterations in mouse healthy tissues. Additionally, we revealed the collaborative 
interaction between FGF-2 and VEGF-C in promotion of lymphangiogenesis and metastasis.  
In paper I, using two independent tumor models, we show that PlGF modulated tumor growth, 
angiogenesis, and vascular remodeling through a VEGF-dependent mechanism in either a 
positive or a negative manner. In the VEGF-A positive model, PlGF inhibited tumor growth 
and angiogenesis, leading to normalized tumor vasculature with dilated vessel lumens, 
infrequent vascular branches and increased perivascular cell coverage. Surprisingly, in the 
VEGF-A negative model, overexpression of PlGF resulted in the opposite phenotype to that 
seen in the VEGF-A positive model, namely accelerated tumor growth rates and abundant 
chaotic tumor vessels. Our data uncovered the molecular mechanisms underlying the 
complex interplay between PlGF and VEGF-A. These findings have conceptual implications 
for anti-angiogenic cancer therapy.  
In paper II, we show that tumors from humans and mice with high levels of expression of 
PlGF were hypersensitive to anti-VEGF-A and anti-VEGFR-2 therapies. We then validated 
this finding with a loss-of-function experiment using PLGF shRNA in a human 
choriocarcinoma cell line. Down-regulation of PlGF significantly accelerated tumor growth 
rate and led to resistance to anti-VEGF drugs. We also show that VEGFR-2 and VEGFR-1 
neutralizing antibodies displayed opposing effects on tumor growth and angiogenesis. These 
findings demonstrate that tumor-derived PlGF negatively modulates tumor angiogenesis and 
sensitizes treatment effect of anti-VEGF drugs in VEGF-A positive tumors, PlGF level in 
VEGF-A positive tumor may potentially be a predictive marker of anti-VEGF cancer therapy.  
In paper III, we investigated vascular alteration in various organs after systemic treatment 
with anti-VEGF-A, anti-VEGFR-1 and anti-VEGFR-2 neutralizing antibodies. This study 
provides functional and structural mechanisms for anti-VEGF drug-induced adverse effects in 
patients.  
In paper IV, we looked into the role of fibroblast growth factor-2 (FGF-2) and VEGF-C on 
angiogenesis, lymphangiogenesis and tumor metastasis. The results showed that FGF-2 and 
VEGF-C could both separately and collaboratively promote angiogenesis and 
lymphangiogenesis in the cornea of the mouse and in the mouse tumor tissue, resulting in 
pulmonary and lymph node metastases in animal models. By blocking VEGFR-3 and FGF 
receptor-1 (FGFR-1), we also revealed the fact that VEGFR-3-induced lymphatic endothelial 
cell (LEC) tip formation is a necessity for FGF-2-FGFR-1 signaling stimulated 
lymphangiogenesis. This study suggests that combined targeting of FGF-2 and VEGF-C 
might be an effective approach for cancer therapy and prevention of metastasis. 
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1 INTRODUCTION 
1.1 TUMOR ANGIOGENESIS 
1.1.1 Functions and architecture of vessels 
In all vertebrates, vessels, including blood vessels and lymphatic vessels, comprise a 
transportation network for plasma, blood cells, oxygen, nutrition and metabolites throughout 
the whole body, which is essential for normal physiological functions and has implications in 
various pathological states1. The lymphatic vasculature is also involved in tissue fluid 
homeostasis, the absorption of dietary fat, and the functioning of the immune system2. 
Blood vessels are divided into three major types according to their function and structure:  the 
arteries are responsible for carrying the oxygenated blood away from the heart; the veins 
return blood from the capillaries back to the heart and the capillaries are the smallest unit of 
blood vessels and are the sites of substance exchange between the blood and tissues3.  
Lymphatic vessels consist of two types of networks—the initial lymphatic capillaries that 
specialize in collection of the lymph from the interstitial fluid, and the larger lymph vessels 
that is responsible for the drainage of the lymph3,4. 
There are recognizable structural differences between typical blood capillaries and lymphatic 
capillaries. The endothelial cells (ECs) of blood vessels are connected with each other by 
tight junctions and are entirely covered by basement membrane together with contractive 
mural cells—pericytes and smooth muscle cells. Inversely, the lymphatic vessels start as 
small blind-ends, have no basal lamina, and the ECs are anchored to the adjacent matrix, 
which results in the vessels being open to the interstitial space5. When the interstitial fluid 
pressure (IFP) rises, while the blood capillaries may collapse, the lymphatic vessels open, 
allowing more interstitial fluid to return to the lymphatic system2, 4, 5. 
ECs are the indispensable component of all vessels as they line the interior surface of the 
vessels and depart the fluid phase from the tissues. The ECs located in different organs 
participate in various bioactivities, for example, hemostasis, coagulation (thrombosis and 
fibrinolysis), fluid filtration, arteriosclerosis blood vessel tone, inflammatory recruitment and 
infiltration, hormone trafficking, and most importantly, they play a very important role in 
angiogenesis by migration, proliferation and secretion of certain angiogenic factors6, 7, 8. 
The mural cells are another basal structure of the vessel wall. Pericytes are the mural cells of 
capillaries and venules; smooth muscle cells are the mural cells of other blood vessels. 
Beneath the ECs, the pericytes line the interior of the basal membrane, and discontinuously 
cover the vessel wall. They communicate with the ECs by paracrine signaling or direct cell 
junction, and strengthening the barrier between capillary well and surrounding tissues9, 10, 11. 
Gap junctions between pericytes and ECs allow the exchange of ions and small molecules. 
Interestingly, cell-cell contact appears necessary for vessel formation and maintenance12, 13. 
The second class of mural cells, smooth muscle cells (SMAs), which are usually located 
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exterior of the basal membrane, control the vasoconstriction and vasodilation together with 
pericytes14. 
As a part of tumor microenvironment, the properties of capillaries in tumor tissue contribute 
to every stage of tumor progression and metastasis15. 
1.1.2 Angiogenesis 
More than 220 years ago, the Scottish surgeon Dr. John Hunter first proposed that there is an 
equilibrium between vascularity and metabolic needs in both healthy and diseased states, 
which means that the vasculature changes along with the physiological and pathological 
status of the human body16. This concept was revisited in 1971 by Dr. Judah Folkman who 
stated the study of angiogenesis by hypothesizing that tumor growth is angiogenesis-
dependent and describing interactions between ECs and tumor cells via tumor-angiogenesis 
factor17. From then on, the field of angiogenesis research was established and studied by 
more and more scientists from all medical and biological fields.  
Throughout life, there are two ways of blood vessel formation—“vasculogenesis” and 
“angiogenesis” 18. Vasculogenesis indicates new vessel formations when there are no pre-
existing vessels, whereas, angiogenesis refers to the process of new vessels sprouting from 
pre-existing vessels19, 20. Vasculogenesis and angiogenesis are indispensable in embryonic 
development, tissue regeneration, and the female reproductive system, for example, during 
the menstrual cycle and development of corpus luteum. It also contributes to many 
pathological disorders, such as cancer, age-related macular degeneration, obesity, asthma, and 
arthritis7, 10, 21, 22.  
Until now, four different bio-mechanisms of angiogenesis have been defined and all of these 
can be found in tumor development: sprouting, intussusception, mimicry and cooption. 
1.1.2.1 Sprouting 
Sprouting angiogenesis includes the oriented filopodia extension of the tip cells and 
proliferation of the stalk cells induced by certain angiogenic factors including vascular 
endothelial growth factor-A (VEGF-A), angiopoietin-1 (Ang-1), fibroblast growth factor 
(FGF-2), delta-like 4 (Dll4) 23, 24, 25, 26, 27 (See 1.1.4). Gerhardt et al. observed that the retina 
vessel sprouting is controlled by agonistic activity of VEGF-A whereby 
the tip cells migration is correlated with an increased concentration of VEGF-A, and in the 
meantime, the stalk cells proliferate upon reaching a concentration threshold of VEGF-A23. 
1.1.2.2 Intussusception 
Intussusceptive angiogenesis, also called vascular splitting denotes vascular network 
formation by protrusion of interstitial tissue columns (tissue pillars or posts) into the vascular 
lumens, and further transluminal pillars are formed, resulting in new vessel lumens 
formation28, 29. Intussusceptive angiogenesis not only depends on angiogenic growth factors30, 
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31, 32, 33 but is also regulated by intravascular blood-flow patterns or intravascular shear stress 
which is a potent trigger of intussusception34. 
1.1.2.3 Mimicry 
Vascular mimicry describes how highly aggressive tumor cells organize or mimic the vessel-
like structure with basal membrane and extracellular matrix (ECM) but without presence of 
ECs and mural cells35. Vascular mimicry has been observed in several tumor types, and was 
initially found in malignant melanoma by Dr. Hendrix 36, followed by its discovery in breast 
cancer by Dr. Wakasugi 37. Vascular mimicry reminds us that aggressive tumor cells exhibit 
high plasticity and pluripotency, and mimicry is strongly associated with poor prognosis38. 
1.1.2.4 Cooption 
Holash et al. first defined vessel cooption when they found that tumor cells migrated toward 
host blood vessels in well-vascularized organs or in a metastatic site to support blood vessel-
dependent tumor growth instead of triggering angiogenesis. These vessels then regress 
because of apoptosis mediated by Ang-2 expressed by the coopted ECs. Later on, 
angiogenesis began at the periphery of the growing tumor mass39. Vessel cooption happens 
during the early stage of tumor development and is dependent on the site of the tumor, often 
in the brain and lung40, 41. 
1.1.2.5 Vasculogenesis 
Vasculogenesis is the mechanism by which mesoderm-derived angioblasts (endothelial 
precursor cells) migrate and differentiate into ECs to form primitive blood vessels. 
Vasculogenesis mainly occurs during embryonic development of the cardiovascular system 
and some researchers also found it in adult pathological conditions, for example during 
hemangioma formation42.  
1.1.2.6 Lymphangiogenesis 
The cellular processes of lymphangiogenesis are considered to be similar to that of 
hematoangiogenesis—the lymphatic vessels inside or surrounding the tumor mass undergo 
sprouting and enlargement contributed by migration and proliferation of lymphatic 
endothelial cells (LECs). These patterns of lymphatic remodeling have been found in various 
primary human cancers43. Studies on tumor lymphatic vessels mainly focus on the ability of 
lymphatic capillaries to facilitate the entry and transport of tumor cells5, 43, 44, 45, 46, 47. 
1.1.3 Tumor vessels 
Angiogenesis is a prerequisite for the process of solid tumor growth and metastasis. When the 
tumor size reaches to several millimeters in diameter, the tumor will be deprived of oxygen 
and nutrition since molecules cannot reach to the center of tumor by diffusion. The hypoxic 
environment in the tumor will trigger tumor angiogenesis. However, compared to healthy 
tissue, tumor vessels have numerous special properties that may facilitate cancer progression 
and tumor cell intravasation, as well as the development of resistance to anti-angiogenic 
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treatment21, 48, 49. ECs, pericytes, and the vascular basement membrane in tumor vessels are 
all structurally and functionally abnormal, which causes problems when it comes to 
identification of the tumor vessels50, 51. Structurally, tumor vessels do not have a typical 
arteriole–capillary–venule hierarchy that is seen in normal tissue. Instead, abundant 
endothelial sprouting branches are widespread, and some ECs are partially detached or form 
incomplete layers50, 52. Tumor blood vessels are often irregular, chaotic, tortuous, lack of 
mural cell coverage and have a relatively higher density compared to normal vasculature. 
Pericytes of tumor vessels associate with ECs loosely and can even detach from the ECs53. 
Functionally, tumor vessels are poorly perfused and with greater leakiness, some ECs just 
sprout in a haphazard manner or form a vessel lumen without blood flow. Conversely, some 
routes of blood flow are not lined by ECs. These features of tumor vessels endow the tumor 
microenvironment with high IFP and hypoxic level17, 54, 55. 
1.1.4 Angiogenic stimulators 
Angiogenesis depends a complex set of cellular events, including proliferation, sprouting, 
migration and tube formation. The series of cellular events in hematoangiogenesis and 
lymphangiogenesis may be similar and some blood vessel regulators are involved in 
lymphatic development as well. In this section, I will briefly introduce several principal pro-
angiogenic factors and their roles in tumor angiogenesis, excluding VEGF family members. 
1.1.4.1 Fibroblast growth factor-2 (FGF-2) 
FGF-2 is a heparin-binding protein that was shown to be a potent pro-angiogenic factor56. It 
promotes neovascularization by stimulating proliferation and migration of ECs, as well as 
degradation of the ECM through up-regulation of proteases, e.g. matrix metalloproteases 
(MMPs) and urokinase-type plasminogen activator (uPA)57, 58. FGF-2 is highly expressed by 
ECs, infiltrated inflammatory cells and various tumor cells, such as prostatic cancers, 
hematological malignancies, melanoma and pancreatic tumors56, 59, 60, 61, 62. This indicates that 
FGF-2 may act on all these components via autocrine or paracrine signaling. Under these 
conditions, FGF-2 may facilitate cancer progression not only by promoting angiogenesis but 
also by acting directly on tumor cells and tumor-associated macrophages62, 63, 64.  
FGF-2 was also shown to be a very strong lymphangiogenic factor through activations of 
FGF receptor-1 (FGFR-1) and FGFR-3. It has been shown that FGF-2 can also stimulate 
lymphangiogenesis through up-regulation of VEGF-C65, 66, 67. 
In paper IV, we uncovered the mechanism that lymphangiogenic factors, VEGF-C and FGF-
2, collaboratively stimulate lymphangiogenesis via VEGF receptor-3 (VEGFR-3) and FGFR-
1 transduced signaling pathways. 
1.1.4.2 Platelet-derived growth factor-BB (PDGF-BB) 
The role of PDGF-BB and PDGF receptor-β (PDGFR-β) in angiogenesis is to promote 
recruitment, migration and proliferation of mural cells68, 69, 70. In one of our published works, 
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in addition to abundant PDGF-BB stimulated angiogenesis, we surprisingly found 
bidirectional modulation of pericytes recruitment to the tumor vessel by PDGF-BB. Tumor 
cell-derived PDGF-BB detached the pericytes from ECs, whereas, ECs attracted the pericytes 
by producing PDGF-BB71.  
Additionally, PDGF-BB induced LECs proliferation via activation of mitogen-activated 
protein kinases (MAPK) as well as enhancing cell motility, thus resulting in intratumor 
lymphangiogenesis and lymph node metastasis in a mouse tumor model72. Later, a clinical 
study demonstrated that PDGF-BB expression level correlated with lymphatic invasion of 
human esophageal carcinoma72. Recently, prospero homeobox protein 1 (Prox-1) was found 
to be the responsible transcription factor for maintenance of PDGFR-β73. 
1.1.4.3 Neuropilins (NRPs) 
NRPs were originally isolated from the nervous system of Xenopus74. They are the major 
receptors of class 3 semaphorins, which play a critical role in several physiological processes 
including acting as anti-angiogenic factors75, 76. They also participate in angiogenesis as co-
receptor of the VEGF family. It has been shown that, VEGF-B and placental growth factor 
(PlGF) binds to NRP-1, and VEGF-A, VEGF-C as well as VEGF-D can bind to both NRP-1 
and NRP-277. NRP-1 is considered critical for vascular formation since Nrp1-/- transgenic 
mice die in utero at E13.5 due to severe angiogenic defects78.  
NRP-2, modulates the VEGF-C signaling pathways as a co-receptor of VEGFR-379. Genetic 
deletion or antibody neutralization of NRP-2 can block VEGF-C induced lymphatic vessel 
sprouting in vivo80.  
Moreover, there are some other angiogenic factors binding to NRPs, such as PDGF-BB and 
FGF-281, 82. 
1.1.4.4 Angiopoietins (Angs) 
To date, four isoforms of Ang have been identified and all of them bind to tyrosine kinases 
with immunoglobulin-like and EGF-like domains 1 (TIE-1) and TIE-2 receptors39. The Angs 
and TIE receptors are essential to development and maturation of the vascular system. 
Knockout of any one amongst Ang-1, Ang-2, TIE-1 and TIE-2 are embryonic lethal or result 
in early postnatal death due to impaired vessel formation83, 84, 85, 86. TIE receptors are mainly 
expressed on ECs, however, they can be detected on myocardium and on hematopoietic stem 
cells87, 88. During angiogenesis, Angs-TIEs axes are responsible for vessel formation and 
stabilization through a complicated equilibrium among all members: Ang-1 strongly activates 
TIE-2 signal transduction, while Ang-2 acts as an antagonist of Ang-1, however, Ang-2 has 
very weak stimulatory effect on TIE-2 compared to Ang-1. In addition, TIE-1 may regulate 
function of TIE-2 by forming heterodimers with TIE-289,10, 84.  
Lymphangiogenesis is stimulated by Ang-1 via both direct and indirect mechanisms: Direct 
mechanism is due to activation of TIE-2 expressed on LECs, and indirect stimulation is due 
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to up-regulated VEGFR-3 expression90. Interestingly, one knockout and rescue experiment 
indicated that Ang-2, considered as an antagonist of TIE-2 during angiogenesis, actually acts 
as an agonist in lymphangiogenesis85.  
1.2 VEGF FAMILY IN TUMOR DEVELOPMENT 
Among all the pro-angiogenic factors, VEGF family members play the central roles in tumor 
angiogenesis. In this section, I will discuss more about the VEGF family, the ligands, the 
receptors, their structures, the signaling transductions, the biological function and especially 
how they affect tumor angiogenesis and contribute to tumor growth and metastasis.  
VEGF-A is the major representative of the VEGF family, usually in the literatures, “VEGF” 
points to both “VEGF family” and “VEGF-A”. To avoid confusion upon the terms, in this 
thesis, the “VEGF” only refers to “VEGF family” but not “VEGF-A”. 
1.2.1 Introduction of VEGF family 
Up to date, in total 7 members of the VEGF family have been identified, including five 
ligands from the mammalian genome: VEGF-A, VEGF-B, VEGF-C, VEGF-D and PlGF, 
one analogue ligand from Orf virus—VEGF-E (Orf-VEGF)91, and one analogue from 
Trimeresurus flavoviridis—T. f. svVEGFs (VEGF-Fs)92. In this thesis, I will focus on the 
five factors coded by mammalian genes, which are all crucial during embryonic development. 
The genesis of new blood vessels and lymphatic vessels is controlled by these ligands 
activating three tyrosine kinase receptors—VEGFR-1, VEGFR-2 and VEGFR-3. 
According to their receptor binding pattern and functions, we classified these five VEGF 
family members into three subgroups. PlGF and VEGF-B belong to subgroup as they bind 
exclusively to VEGFR-1. Generally, VEGFR-1 is widely expressed on blood ECs but not 
found on the LECs. The second subgroup consisting of VEGF-A, binds to both VEGFR-1 
and VEGFR-2, VEGFR-2 is expressed mainly on blood ECs but weakly on LECs of 
collecting lymphatic vessels. The last subgroup includes VEGF-C and VEGF-D, both of 
which can activate principally VEGFR-3 as well as VEGFR-2. VEGFR-3, as a marker of 
LECs and is the main lymphangiogenesis related receptor that is structurally different from 
VEGFR-2 and VEGFR-193, 94, 95.  
As typical tyrosine kinase receptors, activation of VEGFRs requires ligand dimer to bind to 
and dimerize two adjacent VEGFR monomers, leading to phosphorylation of tyrosine 
residues in the intracellular tyrosine kinase domain. This phosphorylation leads to the 
formation of a binding site for specific proteins, further initiating the signal transduction 
cascade96.  
1.2.2 VEGF-A 
VEGF-A (formerly known as vascular permeability factor/VPF) was identified separately by 
Senger et al. in 1983 and Ferrara et al. in 198997, 98. It is a glycoprotein capable of undergoing 
dimerization forming two subunits which are connected by disulfide bonds.  The human 
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VEGFA gene expresses several different isoforms of VEGF-A: VEGF-A121, VEGF-A145, 
VEGF-A165, VEGF-A189, and VEGF-A206. The highly homologous rodent VEGF-A 
proteins lack one amino acid compared to the human orthologs99. Owing to various splice 
variants of the heparin-binding domain, different VEGF-A isoforms have different levels of 
solubility. For example, among three major isoforms, VEGF-A121 is completely soluble, 
VEGF165 is moderately soluble, but VEGF-A189 is almost insoluble100. The most important 
isoform in vivo is the VEGF-A165, which is expressed in a variety of cells in the body. 
Isoform-specific mutant mice bearing either VEGF-A120 or VEGF-A188, but not VEGF-
A164, were embryonic lethal due to severe defective vessel development, indicating that the 
isoform VEGF-A164 is essential and sufficient for the normal development of the circulatory 
system101, 102. Additionally, VEGF-A164 binds to NRP-1 that is a co-receptor for the 
collapsin/semaphorin family mediating neuronal cell guidance103, 104. VEGF-A is essential for 
embryonic and early postnatal development. The single allele knockout of Vegfa leads to 
embryonic lethality105, 106. 
VEGF-A is the main stimulator of angiogenesis. As a strong mitogen of ECs, it controls 
proliferation, survival, and migration of the ECs by activating VEGFR-2 and VEGFR-1. 
VEGF-A can be secreted by tumor cells as well as normal tissue cells, and diffuses to the 
surrounding area, eventually binding to VEGFRs on the ECs107. Abundant vessels prompted 
by VEGF-A alone are tortuous and leaky just like the typical tumor vessels described in 
section 1.1.3. 
It is still controversial when it comes to the lymphangiogenic effect of VEGF-A. Kubo et al. 
showed in their experiments that VEGF-A could only induce blood angiogenesis not 
lymphangiogenesis using a mouse cornea assay. However, Dr. Hirakawa detected VEGFR-2 
level tumor-associated lymphatic vessels, under his experimental conditions, VEGF-A 
promoted proliferation of LECs, resulting in tumor metastasis to the sentinel and distant 
lymph nodes65, 108. 
VEGF-A significantly increases vascular permeability through the activation of VEGFR-2109. 
Some studies also revealed that VEGF-A has immunosuppressive properties, e.g. induces the 
accumulation of immature dendritic cells110. Additionally, VEGF-A is involved in 
hemodynamics by controlling the vasoconstriction and vasodilation111, 112. 
It is well known that the tumor possesses a hypoxic core with nearby necrotic when the tumor 
grows to a critical size. Hypoxia is a very potent stimulator of hundreds of genes, and it is 
central to the induction of VEGF-A. On one hand, hypoxia can stabilize hypoxia inducible 
factor 1-α (HIF1-α) and HIF2-α which bind to HIF hypoxia-responsive element of the Vegfa 
promoter, inducing the transcription of DNA. In addition to direct transcription, hypoxia can 
also lead to the stabilization of VEGF-A mRNA113. Thereafter, VEGF-A can be secreted by 
various hypoxic cells, and diffuse to the surrounding zone, to promote new vessel formation 
and relieve the tissue from hypoxia107, 113, 114. 
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1.2.3 VEGF-B 
VEGF-B was first isolated in 1996, and two isoforms were identified, VEGF-B186 and 
VEGF-B167115. Both VEGF-B isoforms bind to VEGFR-1 and the co-receptor—NRP-1. The 
isoform VEGF-B167 possesses the heparin-binding domain, whereas VEGF-B186 does not 
contain the heparin-binding domain116, 117. Vegfb-/- mice developed normally except for minor 
defects during cardiovascular formation and revascularization118, 119.  
Studies on the role of VEGF-B in angiogenesis mainly focus on heart and brain tissue 
revascularization. When it comes to tumor vessel angiogenesis, limited research has been 
conducted. It is reported that VEGF-B increased the mRNA level of uPA and Plasminogen 
activator inhibitor-1 (PAI-1), but not tissue plasminogen activator (tPA) activity in certain 
ECs in vitro116, however, VEGF-B did not show pro-angiogenic activity in our tumor bearing 
mice model and many other studies in vivo120. More and more clinical studies show that the 
VEGF-B levels in tumor tissue correlated with tumor progression and a worse prognosis121, 
122, 123, 124. Recently, a study on biological activities of VEGFR-1 demonstrated that, unlike 
PlGF, VEGF-B may not efficiently induce downstream signaling of VEGFR-1125. whereas, it 
has been shown that VEGF-B is able to form heterodimers with VEGF-A in vitro, thus 
VEGF-B may be able to regulate the activity of VEGF-A126.  
1.2.4 VEGF-C and VEGF-D 
In the VEGF family, there are two members that has been shown experimentally to contribute 
to lymphangiogenesis—VEGF-C and VEGF-D. These are the most well-known 
lymphangiogenic stimulators that activate VEGFR-2 and VEGFR-3. Activation of VEGFR-3 
stimulates protein kinase C-dependent activation of the extracellular-signal-regulated kinase 1 
(ERK1) or ERK2 signaling cascade and phosphorylation of protein kinase B (PKB, also 
known as AKT), leading to survival, proliferation and migration of LECs39, 40, 127, as well as 
lymphatic smooth muscle cells alteration at the collecting lymphatic vessels128. 
People used to think that lymphatic capillaries cannot grow into the tumor due to their thin 
and are structurally weak. Several studies showed that VEGF-C and VEGF-D promoted 
lymphatic metastasis by inducing intratumoral and peripheral lymphatic vessels growth via 
binding to VEGFR-3129, 130, 131.  
Joukov et al. isolated VEGFC cDNA from prostatic cancer and determined that VEGF-C 
binds to tyrosine kinase receptor VEGFR-3 and VEGFR-2132, 133. The homozygous Vegfc 
knockout mice aborted between E15.5 and E17.5 due to severe swelling caused by the 
absence of lymphatics, and whilst the heterozygous can survive, they show hypoplasia of 
cutaneous lymphatics127.  
VEGF-D was initially termed the c-fos-induced growth factor (FIGF) when it was isolated 
for the first time, and was found to be a mitogenic factor for fibroblasts134. VEGF-D has a 
very similar protein structure to VEGF-C and has been shown to bind to the same receptors. 
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Due to these similarities, in a zebrafish model, Vegfd could rescue loss of Vegfc and 
compensate for its function in lymphatic sprouting135.  
1.2.5 PlGF 
PlGF exclusively binds to VEGFR-1. As the name suggests, PlGF is mainly expressed in the 
placenta, however, it is also detectable in the heart, lung and skeletal muscle at lower levels. 
The gene for PlGF in humans code for four isoforms, they are PlGF-1, PlGF-2, PlGF-3 and 
PlGF-4, whereas, only PlGF-2 exists in the mouse136.  
Genetic ablation of PlGF does not affect vessel structure during physiological development137 
but it dose alter angiogenesis during pathological conditions such as hypoxic brain, 
myocardial ischemia, and wound healing137, 138. Studies examining the effects of PlGF on 
tumor angiogenesis and progression were controversial. On one hand, it is demonstrated that 
PlGF suppressed tumor growth in mouse models of LLC and fibrosarcoma, and led to the 
dilation of the tumor vessels and inhibited vessel branching139. On the other hand, 
overexpression of PlGF in mouse melanoma increased the tumor growth and pulmonary 
metastases through activation of MMPs and tumor angiogenesis140. 
Additionally, since VEGFR-1 is involved in recruitment of monocytes and macrophages, thus 
PlGF may promote angiogenesis indirectly by attracting inflammatory cells that secret pro-
angiogenic factors141. It has been reported that PlGF reconstituted hematopoiesis by 
recruiting VEGFR-1+ stem cells from bone marrow. 
In paper I, we uncovered the mechanism by which PlGF regulates VEGF-A-VEGFR-2 
signaling in both a negative and a positive manner by heterodimerization with VEGF-A and 
competitive binding to VEGFR-1. In paper II, we demonstrated that PlGF in tumor cells led 
to sensitization of the tumors to anti-VEGF therapy. 
1.2.6 VEGFR-1 
The function of VEGFR-1 is uncertain and quite controversial. When both alleles of Vegfr1 
were deleted, the mice embryos showed hyper-proliferation of ECs and are aborted early in 
development142. Whereas, if only the tyrosine kinase domain from VEGFR-1 was deleted, the 
mice developed normally143, however, isolated monocytes showed impaired migration in 
vitro under stimulation from VEGF-A and PlGF144. Downstream signaling pathway of 
VEGFR-1 is still an enigma until today145.  
1.2.7 VEGFR-2 
In contrast to VEGFR-1, the role of VEGFR-2 in angiogenesis is relatively well elucidated. 
After receptor undergoes dimerization and autophosphorylation of the tyrosine kinase 
residues on the intracellular domain, it is capable of activating of various pathways, primarily: 
(1) The phospholipase C (PLC)-/protein kinase C (PKC) pathway, leading to the beginning 
of the c-Raf-MEK-MAPK cascade and cell proliferation. (2) The PI3K-Akt signal 
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transduction pathway, contributing to cell survival. (3) The p38 MAPK signaling pathway, 
resulting in cell migration and, (4) eNOS activation for vascular permeability109, 146, 147. 
1.2.8 VEGFR-3 
VEGFR-3 is the major receptor for VEGF-C and VEGF-D and is essential for the 
development of the lymphatic vessels. Primitive lymphatic vessels are transdifferentiated 
from the Prox-1+ embryonic veins, 148,  the Prox-1+ cells undergo differentiation and form the 
lymphatic vessels when they were exposed to VEGF-C which activates the VEGFR-3 on 
these cells. The VEGFR-3 is eventually shifted from the embryonic veins to the lymphatic 
vessels and became a specific marker of lymphatic vessels149, 150. Despite this, VEGFR-3 can 
also be expressed on blood capillaries in tumor angiogenesis or during wound healing151, 152. 
Similar to Vegfc knockout mice, complete deletion of the Vegfr3 gene causes early embryonic 
death due to defective blood vessel development in embryos—the large vessels’ lumens 
develops abnormally, leading to serious edema and cardiovascular failure at E9.5153, 154.  
1.3 ANTI-VEGF CANCER THERAPY 
Based on Dr. Judah Folkman’s hypothesis that all solid tumor growth is dependent on 
angiogenesis, anti-angiogenic therapy could be considered to be an efficient way of inhibiting 
tumor growth. The aim of anti-VEGF treatment is to prevent the activation of VEGFR and 
the downstream signaling pathways, thus hindering the neovascularization in tumor tissue, 
and eventually resulting in tumor vessel regression and markedly reduced tumor growth. 
Some possible ways of inhibiting VEGF signals include: (1) Neutralizing antibodies that 
block the VEGF family ligands. (2) Neutralizing antibodies that block the VEGFRs, thus 
obstructing activation of the receptors. (3) Soluble receptors with the ligand-binding domain 
of membrane receptors, acting as decoy for the ligands before they bind to the receptors on 
the cell surface. (4) Small molecules that block ligand-binding sites on VEGFRs. (5) 
Tyrosine kinase inhibitors (TKIs)—small molecules with the ability of crossing the cell 
membrane that bind to the tyrosine kinase domain of the VEGFRs to inhibit the activation of 
downstream signaling pathways. (6) RNA interference technology.  
1.3.1 Neutralizing antibodies 
In the past 20 years, a few non-human antibodies were developed and their efficiency were 
validated using mice model in preclinical experiments. These heterogenic antibodies may 
induce the human immune response if they are directly introduced into patients, therefore 
humanization of the antibodies is required. Usually, the standard way of humanizing an 
antibody is to transfer the specific binding region to a human antibody framework155.  
Nowadays, anti-VEGF-A antibodies are the most well-developed blockades among the anti-
angiogenic treatments since the function of VEGF-A is well understood. Dr. Ferrara made the 
first anti-VEGF-A antibody called A4.6.1156. Later, A4.6.1 was humanized into bevacizumab 
(Avastin, Genentech/Roche) which is the first monoclonal antibody approved to treat 
malignant cancer. Recently, ranibizumab (Lucentis, Genentech), a smaller neutralizing 
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antibody containing only the fragment antigen-binding (Fab) domain of IgG was derived 
from bevacizumab, it has 140 times higher affinity for VEGF-A than bevacizumab157, but 
until now, ranibizumab is only approved for macular diseases. 
Early this year, a human VEGFR-2 antagonist (ramucirumab) developed by Eli Lilly and 
Company was approved by the Food and Drug Administration (FDA) for treatment of 
advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent 
after prior fluoropyrimidine- or platinum-based chemotherapy158.  
1.3.2 Soluble receptors 
Regeneron Pharmacerticals generated a decoy receptor that is a fusion protein of domain 2 
from VEGFR-1, domain 3 from VEGFR-2 and an IgG Fc. This VEGF trap blocks not only 
VEGF-A but also PlGF and VEGF-B159. It is approved for metastatic colorectal cancer 
(mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen, 
and is marketed under the commercial name ZALTRAP160.  
In addition, tumor lymphangiogenesis is clearly associated with the lymphatic metastasis. To 
block the lymphagiogenesis pathway, soluble VEGFR-3 was developed by fusing the 
VEGFR-3 domain to an IgG fragment crystallizable (Fc) region. This fusion product 
inhibited lymphangiogenesis and lymph nodes metastasis in a murine tumor model161 and 
ablated lymphangiogenesis in embryonic mice162.  
 

 13 
 
2 AIMS 
The overall aim of this thesis was to investigate the role of VEGF family members in tumor 
angiogenesis, tumor growth, and metastasis. 
The specific aims included:  
To explore the mechanism of VEGF-A dependent PlGF induced tumor vessel remodeling. 
To elucidate the role of PlGF in anti-VEGF drug resistance and sensitivity. 
To study the systemic effects of VEGF targeting drugs. 
To understand the effects of two lymphangiogenic factors VEGF-C and FGF-2 on 
lymphangiogenesis and tumor metastasis, and the interplay between VEGF-C and FGF-2. 
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3 METHODS 
In this section, I will highlight the details in the methods used in our research that require 
extra attention or discussion. The details of each protocol can be found in the constituent 
papers. 
3.1 ANIMAL MODEL 
It is difficult to relate conclusions from an animal experiment directly to clinical practice 
since there are individual variances amongst people as well as many biological differences 
between animals and humans. Despite not being able to relate the situation seen in animals 
directly to humans, in most preclinical studies, animal models are necessity. Laboratory 
animals have identical and homogeneous biological backgrounds, thus it is easier to exclude 
individual variability from a group of model animals in comparison with a human population, 
and therefore a smaller sample size is needed for equal statistical power. Additionally, there is 
better accessibility to a larger sample size when it is required. To manage and collect samples 
from a group of animals is more feasible. The animal models are also able to take over the 
majority of risks during scientific research, for example, the toxicity of a new compound or a 
new therapeutic protocol. These points are important given the in vitro experiments can 
currently not mimic the systemic reaction of a whole organism, or many complex interactions 
seen in the human body. 
3.1.1 Murine tumor xenograft model 
To validate the anti-tumor therapeutic protocol, we have to perform animal experiments. In 
this thesis, we inoculated tumor cells subcutaneously into the mid line dorsal area to be able 
to observe the tumor size accurately in real-time, meanwhile, to avoid influences from 
interscapular and inguinal adipose tissue that are highly vascularized organs. If such close 
observation of the tumor size is unnecessary, the orthotopic tumor model is preferred, 
because it provides an appropriate tumor microenvironment and produces accurate 
phenotypes. 
We measured the tumor size with vernier calipers. And the volume of tumor was calculated 
according to a formula: tumor size = length × width2 × 0.52 if the tumor grew into 
hemispheric mass. If the tumor was not hemispheric, we compensated by measuring the 
dissected tumor mass. The dissected tumor mass was obtained for the JE-3 tumor in paper II 
and the metastatic lymph nodes in paper IV. 
When one treats the mice with antibodies or small molecules, one should consider the 
following issues. Firstly, the best route of drug administration must be decided upon. These 
can be oral (p.o.), intravenous injection (i.v.), or intraperitoneal injection (i.p.). If possible, we 
first select the same route of administration as the clinical application of the drug. An 
example of this would be sunitinib as it is given orally in paper II. Secondly, the 
pharmacological properties should be taken into consideration, for example when a drug 
needs to be cleaved into its functional metabolite by low pH, we have to choose p.o. to 
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transport the drug into stomach. Additionally, we tend to choose the easiest route of 
administration to minimize suffering of the mice. The second point of consideration is to 
optimize the dosage. Every species has specific metabolic rates and other features that affect 
pharmacokinetic parameters, moreover, the sensitivities to the drug also alter in different 
animals. So one should consider the species, age, gender and size of the animal when one 
calculates the dosage, and a pilot experiment using different dosages is often required. 
Finally, we need to sacrifice the mice using different methods according to the ethical permit 
and the purpose of the experiment. If we want to collect blood by heart puncture or the mice 
need to be perfused through heart injection, CO2 inhalation is the best approach. Otherwise, 
cervical dislocation is a good way to prevent undue pain during euthanasia. 
3.1.2 Metastasis assay 
Nowadays, several in vivo metastasis models are frequently used to evaluate every steps of 
distal metastasis. In order to evaluate the capability of tumor cell intravasation, we can check 
the number of fluorescently labeled circulating tumor cells (CTCs) using Fluorescence-
activated cell sorting (FACS) or by blood culture assay71. If tumor cells were injected via the 
tail vein, by observation of the formation of metastatic nodules in distal organs, we can obtain 
information on tumor cell extravasation163. In paper IV, we examined the pulmonary 
metastasis to assess the hematogenous metastasis as the dorsal subcutaneous tumors have the 
tendency to metastasize to the lung. To evaluate lymphatic metastasis, we examined the 
subaxillary lymph nodes, as these are the sentinel lymph nodes for our tumor bearing mice 
model. Recently, we developed a new zebrafish metastasis model with which we can 
ascertain the aggressiveness of a tumor cell line efficiently164. 
3.1.3 Mouse corneal model 
In order to understand the mechanisms behind angiogenesis or examine the capabilities of an 
angiogenic factor to exert an effect, proper biological assays need to be established. In the 
past, a series of in vitro and in vivo assays have been developed and utilized to investigate 
angiogenesis165, 166. The in vivo assays allow us to observe the exact outcomes in a 
sophisticated physiological tumor microenvironment, which can never be reproduced in vitro. 
Amongst all the in vitro assays available, we chose the mouse corneal micropocket assay to 
study angiogenesis and lymphangiogenesis stimulated by FGF-2 and VEGF-C in paper IV 
based on the following considerations: (1) Compared with the chick embryo chorioallantoic 
membrane (CAM) assay and transparent zebrafish embryos, mice have less species 
difference from human beings. (2) Unlike the fragile CAM, the cornea is naturally exposed to 
the air and will not be disturbed by the atmospheric gas levels or unregulated pH. (3) The 
new vessel formation in the cornea is considered to be the most reliable evidence of neo-
angiogenesis, because the mouse cornea is a completely avascular tissue and can avoid 
influence from pre-existing vessels167. (4) According to our previous data, the mouse corneal 
micropocket assay is reliable, stable and quantitative. 
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The stimulators are not placed in the center of the mouse cornea, the new vessels usually 
grow unevenly. In order to compare the quantified data in a reproducible and equitable way 
we divided the whole flat-mounted cornea into four circular sectors and named them 
according to their location relative to the pellets, for example, 1.5-4.5h. After this we can 
compare the vessel area of the whole cornea from each groups, or the vessel area in the same 
sector from different groups. 
3.2 EXPERIMENTAL METHODS IN VITRO 
3.2.1 Cell proliferation assay 
In paper I, II, and IV, we measured the cell proliferation rate using the MTT assay. The basic 
rationale of MTT assay is to detect the formazan product from reducing MTT, which is used 
as an approximation of the amount of MTT taken up by living cells. This is a quick and 
convenient assay, but is not a suitable way of comparing proliferation rates of different cell 
types. This is due to variability of different cell types to reduce MTT. Additionally, the value 
from this assay does not give the exact number of cells in each sample but just provides an 
impression of the relative cell density. The MTT reagent is sensitive to light, so the MTT 
assay should be performed in the dark. Nowadays, other tetrazolium salts have been 
developed to replace MTT, e.g. XTT168, MTS, WSTs169. 
3.2.2 Cell migration assay 
To study the ability of cells to migrate or evaluate chemotaxic strength of an attractor on a 
certain type of cell, target cells and agents were usually assembled into a 3D culture system 
where the cells can be co-cultured with the other cells or factors. The Boyden chamber assay 
is one of the classical ways for studying cell chemotaxis—cell motility toward increasing 
concentrations of soluble attractants. In paper IV, we used the Boyden chamber assay to 
measure LEC migration, as our purpose was to assess VEGF-C and FGF-2 stimulated cell 
migration regardless of the effect on cell proliferation and cell-cell interactions. In this 
chamber, ECs generally go through the porous membrane within a few hours, a much shorter 
time than is required for cell division. The other well established systems for evaluating of 
cell migration include the in vitro wound healing assay, the tube formation assay, and the cell 
mobility assay in matrigel170, 171. 
3.3 IMAGING ANALYSIS 
Imaging is an important method to evaluate neo-angiogenesis. The vasculature can be 
distinguished from the surrounding tissues by perfusion reagents, specific vessel markers and 
by cell conformation41, 51. In this thesis, we imaged the vessels with a stereomicroscope 
(Paper IV), a confocal microscope (all papers) and a transmission electron microscope (TEM, 
Paper III). 
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3.3.1 Labeling of targets 
In order to detect a certain group of cells to be able to analyze their location, number or 
morphological features, we label them with specific cell markers. Usually the same marker 
can be shared by different groups of cells while one cell can express several markers, 
therefore we may identify the target cells with more than one markers.  
3.3.1.1 Blood endothelial markers 
CD31 is a widely used immunohistological marker for ECs, therefore it was chosen for this 
thesis. CD31, also known as platelet endothelial cell adhesion molecule-1 (PECAM-1), is a 
pan marker for blood ECs. CD31 is not only highly expressed on the surface of adult and 
embryonic vascular ECs but also expressed on bone marrow stem cells, platelets, 
megakaryocytes, myeloid cells, T lymphocytes, trophoblasts172, and even human brown 
adipocytes173. CD34 is also another frequently used EC marker and is mainly expressed on 
early hematopoietic and vascular-associated tissue. Additionally, endomucin, VEGFR-2, 
and Dll4 amongst others also serve as endothelial markers in diverse studies166, 174. 
3.3.1.2 Lymphatic endothelial markers 
Various proteins have been used as LEC markers, including VEGFR-3149, LYVE-1175, 
podoplanin176, Prox-1148, 177 and NRP-24. In paper IV, LYVE-1 was used for 
immunofluorescence staining to distinguish lymphatic vessels from blood vessels in tumors. 
It is generally expressed on LECs of lymphatic capillaries but not on LECs from collecting 
lymphatics175. 
3.3.1.3 Mural cell markers  
The detection of pericytes is often dependent on certain angiogenic stage of the tissue or in a 
tissue-specific manner12, 13. Neuron-glial antigen 2 (NG2), also known as melanoma-
associated chondroitin sulfate proteoglycan, is the most widely used pericytes surface pan-
marker (Paper I and II). Interestingly, NG2 binds to angiogenic regulators such as FGF-2, 
PDGF-AA and angiostatin178. As the name suggests, NG2 is expressed in the central nervous 
system by oligodendroglial precursor cells and pericytes179. PDGFR-β, also a cell-surface 
protein, is the critical receptor controlling the recruitment of pericytes. It is expressed in 
pericytes progenitors and pre-mature pericyte, however in the mature pericytes, PDGFR-β is 
expressed in lower levels180. Alpha-smooth muscle actin (αSMA) is wildly expressed by the 
smooth-muscle cell lineage and myofibroblasts (Paper I)181. Similarly, desmin is usually 
expressed in muscle cells, including skeletal muscle cells, smooth muscle cells and 
myocardial cells182. Both Desmin and αSMA are normally used as markers of contractive 
mural cells. Additionally, by gene expression profiling, new pericyte markers were identified 
from PDGF-BB deficient embryos183. Regulator of G-protein signaling 5 was found in 
pericytes and smooth muscle cells. Its expression is further induced during angiogenesis. 
Interestingly, Kir6.1 is considered as another specific pericytes marker, but it is detectable in 
special tissue, for example, brain and pancreas69, 183.  
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3.3.2 Imaging 
In this thesis, several microimaging techniques were used to observe alterations in 
angiogenesis. In paper IV, under the stereomicroscope, we saw the gross new blood vessel 
structures but not the lymphatic vessels due to the presence of red blood cells. In paper III, 
TEM allowed us to see the endothelial fenestrations and caveoli directly without labeling as it 
was possible to distinguish the capillary ECs according to their special ultrastructure and 
cellular organelles.  
Confocal microscope imaging is a robust technique to acquire 3D reconstructions of the 
vasculatures. It is also the most frequently used method in our studies. Before scanning, we 
perform a whole mount staining procedure to label the samples with fluorescein and specific 
cell markers. Even though whole mount staining requires fresh tissues and consumes more 
time and reagents, the confocal imaging allows us to: (1) reconstruct the whole 3D structure 
of the vessels, (2) see the deep layer of the sample, (3) obtain precise positional information 
of each component of the tissue, (4) observe the details of the cell in a 3D pattern and (5) 
localize the labeled molecules in the cell184, 185. 
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4 RESULTS AND DISCUSSION 
The constituent papers in this thesis describe the angiogenic effects of VEGF family 
members on the tumor vasculature (paper I, II and IV), the results from the remodeling of 
tumor vessels including impacts on distant metastasis (paper IV) and therapeutic outcomes of 
anti-VEGF treatment (paper II). Finally, paper III illustrated the systemic consequences of 
anti-VEGF treatment. 
4.1 PLGF REGULATES THE TUMOR VASCULATURE AS EITHER A PRO-
ANGIOGENIC OR AN ANTI-ANGIOGENIC FACTOR DEPENDING ON ITS 
HETERODIMERIZATION WITH VEGF-A (PAPER I) 
Despite numerous studies, the role of PlGF in tumor growth and angiogenesis is still 
controversial186. Up-regulation of PlGF has been reported to be a promoter of mouse 
melanoma angiogenesis, growth and metastasis187. However, in another tumor model, 
overexpression of PlGF showed the opposite effects188. 
Why does this debate exist? Bjorndahl et al. have reported that PlGF and VEGF-A 
heterodimerize with each other189. We propose that the different experimental results come 
from the complicated cross-talk of PlGF, VEGF-A, VEGFR-1 and VEGFR-2.  
To simplify the study, we removed the key factor—VEGF-A from this system by choosing a 
VEGF-A-null tumor cell line as the major subject. This mouse fibrosarcoma tumor cell line, 
528ras, was derived from VEGF-A deficient mice embryos, the Ras oncogene was 
transfected into the non-tumorigenic fibroblasts to give rise to a highly tumorigenic and 
fibrosarcoma190. Another mouse fibrosarcoma tumor cell line T241 was used as VEGF-A-
positive control.  
To investigate the function of PlGF on VEGF-A negative and VEGF-A positive tumors, 
PLGF cDNA was cloned into 528ras and T241 cells to yield overexpression of PlGF. 
However, the overexpression of PlGF had no impact on tumor cell proliferation rates in vitro 
(Figure 1A). We then checked the levels of various dimers inside and outside the tumor cells 
by performing a sandwich ELISA assay using cell lysate and cell culture conditioned medium. 
The ELISA data verified that the PlGF/PlGF dimers were markedly up-regulated in PLGF 
transfected cells and the majority of PlGF homodimers were secreted into the conditioned 
medium. Despite this, VEGF-A/PlGF heterodimers were significantly increased in the 
medium of PLGF transfected VEGF-A positive cells. Interestingly, the secretion of VEGF-
A/VEGF-A homodimers was partially prevented by formation of VEGF-A/PlGF 
heterodimers (Table S1).  
We wondered what would happen in tumor vasculature based on the changes of various 
dimers detected in vitro, so we implanted tumor cells subcutaneously into C57BL/6 mice. 
Using the s.c. tumor-bearing mouse model, we monitored the tumor development by 
palpation and measured the tumor size with vernier calipers. Usually, the tumor masses under 
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the skin grew in a hemispherical manner, the volume of tumor was calculated according to a 
formula mentioned above. 
First, we investigated the angiogenic effect of PlGF in VEGF-A positive tumors. One million 
T241 Vector or T241 PlGF tumor cells were injected into each mouse. It took 16 days for 
T241 Vector tumors to grow to 1 cm3. Within the same period, the average volume of T241 
PlGF tumors only reached 0.5 cm3 (Figure 1B lower chart). High levels of PlGF suppressed 
primary tumor development in VEGF-A positive tumor cells.  
We then examined the tumor vessel structure using immunohistofluorescent staining with an 
EC marker—CD31 and a pericyte specific marker—neuron-glial antigen 2 (NG2). Analysis 
of 3D images of intratumoral vessels showed that the average number of vessels per field 
dramatically reduced and the vessels were noticeably more dilated in the PlGF transfected 
tumors. Compared with the T241 vector tumor, T241 PlGF tumor vessels were smoother with 
less branching points. The NG2 signal increased in the PlGF transfected tumors, showin they 
possessed better pericyte coverage (Figure 1C and D). 
Besides the vessel structure, we also explored the functional changes that resulted from PlGF-
induced tumor vessel remodeling, including perfusion and leakage of vasculature in the 
tumors. For this purpose, we perfused the tumor bearing mice with two forms of a 
hydrophilic polysaccharides dextran weighing either 2000 kDa or 70 kDa through the tail 
vein just before euthanasia of the animals. The dextran was labeled with a fluorescent dye 
and conjugated to lysine residues that can subsequently be treated with paraformaldehyde for 
fixation. The dextran perfusion assay showed that improved pericyte coverage in PlGF tumor 
reduced extravasated 70 kDa dextran, and increased the number of 2000 kDa dextran 
perfused vessels due to more organized vasculature in PlGF tumor (Figure 1E and F).  
To validate the phenomena we saw, especially when theses data were inconsistent with 
results from some previous literature, we established another stable high PlGF expressing cell 
line, the Lewis lung carcinoma (LLC) PlGF. We saw the same trend of tumor growth and 
vessel remodeling as in the previous experiment using the T241 PlGF tumors. The growth of 
high PlGF tumors was slower compared to vector tumor and in high PlGF tumors, the vessels 
were dilated and the vascular sprouting was suppressed, resulting in less branch points and a 
greater coverage of pericytes (Figure S1). 
Next, we investigated the angiogenic effect of PlGF in VEGF-A negative tumors. The 
VEGF-A-null tumor cells with or without PlGF overexpression were inoculated 
subcutaneously into immune deficient SCID mice subcutaneously. The same experimental 
procedures were performed and the same parameters were checked and recorded as in the 
T241 tumor cell experiments. Surprisingly, genetic deletion of VEGF-A from the tumor cells 
completely reversed the PlGF induced inhibition of tumor growth and remodeling of tumor 
vasculatures. Compared to the vector control tumors, in VEGF-A-null PlGF tumors we firstly 
saw that tumor growth rate was accelerated by more than 50% (Figure 1B upper panel). 
Secondly, the number of CD31 positive vessels were tripled and the number of branch points 
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doubled. Additionally, the α-SMA marked smooth muscle cell coverage was decreased to 
about 40% (Figure 1C and D). For the vessel function indexes, the extravasated 70 kDa 
dextran was dramatically increased, which indicated very leaky vessels, while the 2000 kDa 
perfused vessel number was significantly decreased(Figure 1E and F).  
The question remained as Why PlGF played a pro-angiogenic role in this tumor model. Did 
the PlGF itself change VEGF-A levels in the tumor? The enzyme-linked immunosorbent 
assay (ELISA) and quantitative real-time PCR data demonstrated that both protein and 
mRNA levels of VEGF-A were not altered by overexpression of PlGF in VEGF-A-null 
tumors (Figure S2C and D). We also examined the tumor-associated macrophages (TAMs) in 
tumor tissue. Our results differed from another study that showed there was an increase in the 
switch from M2-like macrophages to M1 macrophages when PlGF was down-reguated191. 
Our study showed that transfection of PlGF led to a decrease in the number of CD206+ M2-
like macrophages in VEGF-A-null tumors. 
In order to answer whether the angiogenic promotion in the VEGF-A-null PlGF tumor was 
dependent on host-derived VEGF-A, we blocked VEGF-A with an anti-VEGF-A neutralizing 
antibody. We administered the anti-VEGF-A neutralizing antibody (also called VEGF 
blockade in the paper) through intraperitoneal injection, so VEGF-A from all sources should 
be blocked. As a result, the vessel density of VEGF-A-null PlGF tumors was brought down 
to the same level as that of VEGF-A-null vector tumor (Figure 2). These data showed that the 
host-derived VEGF-A was driving factor of angiogenesis in VEGF-A-null PlGF tumors. 
Furthermore, we treated the tumor bearing mice with a VEGFR-2 specific neutralizing 
antibody (DC101, also called VEGFR-2 blockade in the paper) to define the function of 
VEGFR-2 transduced signaling on PlGF stimulated tumor angiogenesis. Comparable to 
VEGF-A blockade, anti-VEGFR-2 treatment inhibited tumor growth and vascular sprouting 
in VEGF-A-null PlGF tumor (Figure 3). This finding verified the critical role of the VEGF-
A-VEGFR-2 signaling pathway in tumor angiogenesis. Interestingly, unlike the data from 
VEGF-A positive tumors, both VEGF-A and VEGFR-2 inhibition did not altered the average 
vessel diameter in VEGF-A-null tumors (Figure 2 and 3). 
4.2 THE RESPONSE TO ANTI-VEGF THERAPY DEPENDS ON THE LEVEL OF 
PLGF IN THE TUMOR (PAPER II) 
The first paper demonstrateed that the interaction between VEGF-A and PlGF affected 
vascular on remodeling. In addition to those findings, the anti-VEGF-A and anti-VEGFR-2 
treatment outcomes gave an idea that the PlGF high expression tumors still respond to anti-
VEGF therapy even without tumor cell-derived VEGF-A.  
With the purpose of uncovering the contribution of the complex interplay between VEGF-A 
and PlGF to the therapeutic efficiency of anti-VEGF treatment, we treated both human and 
mouse PlGF-expressing tumors with several anti-VEGF agents.  
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In order to screen for an appropriate human tumor cell line, we performed ELISA assay to 
measure intrinsic PlGF levels in the conditioned medium of different human tumor cell lines. 
Among all the studied tumors, JE-3 choriocarcinoma expressed the highest level of PlGF, 
which is not surprising because JE-3 choriocarcinoma is a trophoblastic cancer from placenta 
(Table S1). We further looked at the vessel structure in all of these tumor tissues by detecting 
vascular ECs using an anti-CD31 antibody, as expected, the microvessels in the JE-3 tumors 
had normal properties compared with other human tumors, namely a very smooth vessel 
contour line with fewer branching points (Figure S1). We made a JE-3 tumor bearing 
immune deficient SCID mouse model and treated the mice with different anti-VEGF drugs: 
the anti-VEGF-A neutralizing antibody, the anti-VEGFR-1 neutralizing antibody (MF1, also 
called VEGFR-1 blockade in the paper), and the anti-VEGFR-2 neutralizing antibody.  
Our data demonstrated that JE-3 tumors are hypersensitive to anti-VEGF-A and anti-
VEGFR-2 antibodies treatment, but did not respond to anti-VEGFR-1 treatment. At first, the 
tumor growth curve showed that anti-VEGF-A and anti-VEGFR-2 antibodies dramatically 
suppressed tumor growth, while the anti-VEGFR-1 antibody did not change the tumor growth 
rate (Figure 1A and D). The measurement of tumor weight at the experimental endpoint 
showed the same trend. When we examined the tumor vasculature under confocal microscope, 
consistent with the growth curve, fewer vessels or even avascular areas were frequently found 
in anti-VEGF-A and anti-VEGFR-2 treated tumor. In contrast, VEGFR-1 blockade 
surprisingly increased the tumor vessel density and endothelial cell sprouting. All anti-VEGF 
agents also resulted in reduced pericyte coverage on the tumor microvasculatures (Figure 1B 
and E). These findings validate the observation that PlGF-expressing JE-3 tumors were 
highly sensitive to VEGFR-2 blockade.   
In order to know whether the hypersensitivity of JE-3 tumors to anti-VEGF-A and anti-
VEGFR-2 blockades is linked to PlGF, we down-regulated PlGF expression in JE-3 tumor 
cells by PLGF-shRNA transfection. Compared to PLGF-shRNA transfected cells, 
quantitative real time PCR showed that the relative PLGF mRNA level dropped to 40% 
while the VEGFA mRNA level remained constant (Figure 2C), as did the cell proliferation 
rate in vitro (Figure S3B). 
We then treated the control-shRNA JE-3 and PLGF-shRNA tumor bearing mice with 
VEGFR-2 blockade, and measured the growing tumor size every two days. Under these 
conditions, we were able to judge the drug sensitivity by calculating efficiency of inhibition, 
which is presented by T/C value (tumor volume of treated group / tumor volume of control 
group) at both the endpoint and the same-tumor-size point: the smaller the T/C value is, the 
more sensitive the tumors are to the drugs. As shown in figure 2, knockdown of PlGF in the 
JE-3 choriocarcinoma not only accelerated the tumor growth in vivo, but also led to acquired 
drug resistance as determined by a rise in the T/C value. 
To further explore the mechanism of PlGF mediated drug sensitivity to anti-VEGF treatment, 
we established a PlGF-expressing T241 fibrosarcoma cell line, and analyzed various VEGF 
and PlGF dimers levels in cell culture conditioned medium. As expected, T241 PlGF tumor 
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cells secreted a large amount of PlGF/PlGF homodimers and VEGF-A/PlGF heterodimers 
(Table 2). Certainly, as seen previously in our research group, the T241 PlGF tumor grew 
slower than the vector control tumor. In order to exclude the possibility that PlGF directly 
slowed down tumor cell proliferation, we also tested tumor cell growth in vitro and found no 
difference between these two groups. Additionally, the VEGFR-1 and VEGFR-2 mRNA 
levels in tumor cells were also monitored by RT-PCR under the positive control of ECs, but 
neither were detectable. As an extra control, we stimulated the T241 cells with PlGF and 
VEGF-A protein in vitro, and did not see any difference in the rate of cell proliferation 
(Figure S3). 
The T241 tumor bearing mice were then treated with 3 anti-VEGF agents, including VEGF-
A blockade, MF1 and DC101, as well as one tyrosine kinase inhibitor (TKI)—sunitinib. 
Except for VEGFR-1 blockade, all the treatment on T241 tumor gave rise to suppression of 
tumor growth (sunitinib treated data not shown) and inhibition of tumor vessel angiogenesis 
(Figure 3 and 4). Similar to what we have seen in the JE-3 tumor model, high levels of PlGF 
in T241 tumors increased tumor sensitivity to VEGF-A and VEGFR-2 blockade (Figure 3). 
Since PlGF is a VEGFR-1 specific ligand, we were curious about the role of VEGFR-1 in 
PlGF induced tumor growth inhibition and vessel normalization. Therefore, we investigted 
the T241 PlGF tumor vasculature remodeling in Flt1 TK-/- mice in which the tyrosine kinase 
domain of VEGFR-1 was genetically knocked out. Compared with the wild type littermate, 
tumors on Flt1 TK-/- mice had higher vessel density in both T241 vector and T241 PlGF 
group, indicating that Flt1 may transduce a negative signal of angiogenesis. In addition, in 
Flt1 TK-/- mice, T241 PlGF tumors had relatively smoother and fewer dilated vessels than the 
T241 vector tumors, which demonstrate the same trend of normalization as seen in wild type 
mice (Figrue 4E and F). This data pointed out that PlGF induced vessel normalization is 
dependent not only on VEGFR-1 but also on the other signaling pathways. One possible 
explanation may be that this phenotype is a result of the complicated modulation of VEGF-A 
by PlGF mentioned in paper I. 
4.3 VEGF-DEPENDENT PLASTICITY OF VASCULATURE IN HEALTHY 
TISSUE (PAPER III) 
Based on the hypothesis proposed by Dr. Judah Folkman in 1971, several approaches have 
been developed to block or modulate tumor angiogenesis. Tumor angiogenesis is a 
sophisticated procedure involving great number of gene products and different cell types. 
However, VEGF and its signaling pathway is the most important angiogenic factors, thus 
blockades of VEGF signaling are perhaps the best validated anti-angiogenic approaches. It 
has been 10 years since the first specific VEGF-A monoclonal antibody—bevacizumab was 
approved by FDA in the USA to treat certain cancers192, 193. In clinical practice, the side 
effects caused by anti-VEGF agents attract more and more attention nowadays. In order to 
explore the mechanism behind of anti-VEGF agents related side effects, we performed a 
series of preclinical experiments on healthy mice using systemic drug administration.  
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The mice were randomly divided into two groups and treated with a control IgG, or a specific 
anti-VEGF-A IgG. In order to know which receptor was the major receptor responsible for 
vessel alteration from VEGF-A blockade, two more groups of mice were given MF1 or 
DC101. The dosages we applied were previously seen to be able to modify tumor 
angiogenesis. The vessels in all organs were checked under the confocal microscope after 
being marked with an anti-CD31 antibody. Notably, even though the drugs were delivered 
systemically, different tissues reacted to different extents, suggesting vessels in various 
tissues had a distinctive sensitivity to agents blocking the VEGF pathway. (See the table 
below, comparison of vessel density of anti-VEGF drugs treated tissue with that of vehicle 
treated tissue.) 
 
In most tissues, the vasculatures regressed in response to VEGF-A and VEGFR-2 blockades. 
In the endocrine organs that are physiologically more active, the vessels were inhibited the 
most. An example of this would be in the thyroid, nearly 60% reduction of vascular density 
was observed (Figure 1).  
Generally, VEGFR-1 blockade slightly increased the vessel area but did not change the vessel 
density significantly except in the ovaries and uterus. Certainly, as shown by hematoxylin and 
eosin (H&E) staining, there were no detectable structural changes in any tissue. (Figure 1-4)  
Interestingly, tissues in five body compartments, including brain, muscle, bone marrow, 
retina and adrenal medulla did not respond to any of these three anti-VEGF drugs, at least 
when the mice were treated with the doses that we gave. (Shown in the supplementary data) 
In order to further understand the effect of anti-VEGF-A therapy on healthy tissues, we 
focused on the most sensitive organ—thyroid, and investigated further. By using the hypoxia 
probe pimonidazole and examining levels of hypoxia in thyroid tissue, we saw the treated 
thyroid tissue were more hypoxic (Figure 5G). In addition, the immunohistochemical staining 
of cleaved caspase-3 illustrated that a higher percentage of vessel ECs underwent apoptosis in 
the treated thyroid (Figure 5A). We also performed a drug withdrawal experiment to see how 
stable the anti-VEGF-A induced vessel regression was. The vessel density returned to 
untreated level approximately14 days after drug cessation (Figure 5B and C). 
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As mentioned above, the thyroid vessels numbers were dramatically reduced by anti-VEGF-
A treatment, so we also determined the extent by which the function of thyroid could be 
affected. We checked the thyroid hormone level in mouse serum and saw that the free 
thyroxine (T4) level was significantly impaired after only two weeks of treatment (Figure 5F). 
Based on this, we wondered whether the change in thyroid function was due to the 
dysfunctional thyroid vessels. We used dextran perfusion assay described above, to determine 
the health of treated thyroid vessels. The perfusion assay showed less general perfusion due 
to fewer vessels in the treated thyroid, even through the average perfusion of each vessel was 
not altered in response to VEGF-A blockade, the treated thyroid showed less blood perfusion 
because of the lower density of vessels (Figure 5E). Additionally, according to TEM imaging, 
the endothelial fenestration of blood ECs were completely suppressed by anti-VEGF-A, 
leading to an increased number of endothelial caveoli (Figure 5H).  
4.4 FGF-2 PROMOTES LYMPHANIGIOGENESIS AND TUMOR METASTASIS 
VIA VEGFR-3 INDUCED LEC SPROUTING (PAPER IV) 
It is well known that VEGF-C is one of the most important growth factors that controls 
lymphangiogenesis and promotes lymphatic metastasis130, 133, 152, and in LECs, VEGFR-3 is 
the major receptor of VEGF-C. FGF-2 was also identified as a pro-lymphangiogenesis factor 
in previous published papers65, 194. One study has shown that the VEGFR-3 blockade 
inhibited FGF-2-induced lymphangiogenesis in a mouse cornea model, but the mechanism 
underlying this result were not investigated65. In this paper, our data revealed the mechanism 
behind the collaborative interplay between FGF-2 and VEGF-C in promoting angiogenesis, 
lymphangiogenesis and tumor metastasis. 
In order to understand the cellular and molecular effects of VEGF-C or FGF-2 on LECs, we 
treated LECs with VEGF-C, FGF-2, or VEGF-C plus FGF-2. Both VEGF-C and FGF-2 
could independently stimulate proliferation and migration of LECs (Figure 2A, H and I). 
Furthermore, the mRNA levels of FGFR-1 and VEGFR-3 in LECs were increased by both 
VEGF-C and FGF-2 separately (Figure 2E and F). The protein level of phosphorylated 
intracellular signaling molecules, including p-Akt, p-ERK1/2 and p-rpS6, were also increased 
by both VEGF-C and FGF-2 stimulation (Figure 2B and C). In addition, in order to validate 
that FGFR-1 was responsible for FGF-2 stimulated LECs activation, DNA of all FGFRs were 
detected by PCR, the data showed that Fgfr1 was expressed in LEC (Figure 2D) but Fgfr2, 
Fgfr3, and Fgfr4 reminded very week or undetectable. To confirm this data, we performed 
siRNA knockdown of Fgfr1. knockdown of Fgfr1 abolished FGF-2 stimulated LEC 
proliferation (Figure 2G). 
Using a mouse cornea model, we put a tiny piece of polymer pellet containing VEGF-C or 
FGF-2, VEGF-C plus FGF-2, into the artificial micropocket on the avascular cornea. Six days 
later, the corneas were collected to check for neovascularization. Visual inspection of the 
corneas showed remarkable new blood vessel formation in all treated groups (Figure 1A). 
The analysis of LYVE-1+ lymphatic vessels and CD31+ blood vessels showed that either 
VEGF-C or FGF-2 strikingly promoted angiogenesis and lymphangiogenesis, especially the 
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FGF-2 seemed to have stronger angiogenic effect than VEGF-C. Additionally, implantation 
of micropellets containing both FGF-2 and VEGF-C led to synergistic hematoangiogenesis 
and lymphangiogenesis (Figure 1C, G and H). If one looked closely at the LECs, dramatic tip 
formations were triggered by both FGF-2 and VEGF-C (Figure 3A). 
From all the experiments above, we saw very similar effects of FGF-2 and VEGF-C. This 
fact gave rise to the hypothesis that FGF-2 and VEGF-C may share the same signaling 
pathway to initiate the similar outcomes.  
To further discern the major role of FGFR-1 or VEGFR-3 on hematoangiogenesis and 
lymphangiogenesis, we tried to block these two signaling pathways with neutralizing 
antibodies—anti-FGFR-1 and anti-VEGFR-3. The data from in vitro experiments exhibited 
that on one hand, anti-FGFR-1 treatment inhibited the proliferation and migration of LEC 
induced by FGF-2 but not VEGF-C. On another hand, anti-VEGFR-3 treatment could only 
inhibit LEC proliferation and migration promoted by VEGF-C but not FGF-2. This result 
demonstrated that FGF-2 and VEGF-C could independently stimulate LEC via their own 
receptors. We then performed an antibody blockade experiment in vivo. Consistent with the 
in vitro assay, anti-FGFR-1 inhibited FGF-2 induced lymphangiogenesis as well as 
hematoangiogenesis in mouse cornea (Figure 2K). Meanwhile, anti-VEGFR-3 treatment 
reduced cornea lymphangiogenesis and the number of LEC filopodia promoted by both FGF-
2 and VEGF-C, indicating that VEGFR-3-mediated LEC tip formation was required for both 
FGF-2 and VEGF-C induced lymphangiogenesis (Figure 3B). Notably, anti-VEGFR-3 did 
not affect hematoangiogenic activity of either FGF-2 or VEGF-C (Figure 3C). 
In order to explore whether collaboration of FGF-2 and VEGF-C synergistically promote 
tumor hematoangiogenesis and lymphangiogenesis, we established T241 fibrosarcoma cell 
lines which stably overexpress FGF-2 or VEGF-C by gene transfection. T241 FGF-2 or 
VEGF-C cells were separately injected into mice or mixed together at ratio of 1:1 prior 
inoculation.  
As expected from our previous finding, both FGF-2 and VEGF-C overexpression 
significantly accelerated tumor growth. Co-existence of these two factors led to the fastest 
growth rate (Figure 4A). Consistent with the mouse cornea assay, FGF-2 and VEGF-C 
dramatically stimulated tumor angiogenesis as well as intratumoral lymphatic vessel 
formation (Figure 4B and 5A). We then wanted to know how much the high level of 
vascularization contributed to tumor metastasis. We removed the primary tumors when they 
reached to 1.5cm3, and kept the mice for extra 2 weeks. At the endpoint, all mice were 
sacrificed and examined for subaxillary lymph nodes and lung metastases. We checked under 
the microscope and found there were no metastatic nodules found in the lungs of T241 FGF-2 
tumor bearing mice. Around 40% of VEGF-C tumor-bearing mice got lung metastases. And 
up to 70% of T241 FGF-2 plus T241 VEGF-C tumor-bearing mice development pulmonary 
metastases (Figure 4D and E). Examination of sentinel lymph nodes revealed that less than 
40% of T241 FGF-2 tumor-bearing mice had enlarged lymph nodes, while all the mice in the 
other two groups developed subaxillary lymph nodes metastasis (Figure 5D). Compared with 
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the VEGF-C group, metastatic lymph nodes in FGF-2 plus VEGF-C tumor bearing mice 
were larger and had a greater mass (Figure 5C, E and F). Analysis of green fluorescent 
protein(GFP) signal in tumor cells and H&E staining validated the lung and lymph node 
metastases (Figure 4F and 5G). Taken together, these data demonstrate that FGF-2 and 
VEGF-C collaboratively accelerate pulmonary and lymph node metastases by stimulating 
hemato- and lymph-angiogenesis.  
As shown in figure 5H, VEGF-C bind to VEGFR-3 on LECs and stimulate LEC proliferation, 
migration and tip formation, while FGF-2 independently triggers LEC proliferation and 
migration by activating FGFR-1. However, VEGF-C-VEGFR-3 initiated LEC tip formation 
is the necessity for FGF-2–induced lymphangiogenesis. Simultaneously, both VEGF-C and 
FGF-2 promote hematoangiogenesis via signal transduction by VEGFR-2 or FGFRs on blood 
vessel ECs. Therefore, VEGF-C and FGF-2 collaboratively facilitate tumor metastasis 
through both blood vessels and lymphatic vessels. 
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5 CONCLUSION AND PROSPECTIVE  
5.1 DUAL ROLES OF PLGF ON TUMOR ANGIOGENSESIS 
In VEGF-A positive tumor and VEGF-A-null tumor, overexpression of PlGF resulted in 
different alteration on tumor growth and vessel remodeling. Both sets of results can be found 
from previous studies in different research groups. To uncover the underlying mechanisms of 
these conflicting phenomena will answer many questions existing in the field.  
In order to explain the dual roles of PlGF, we should exam the existing research that has been 
conducted in the field. Firstly, it is known that the VEGF-A-VEGFR-2 signaling pathway is 
the major trigger of new vessel formation, This is despite VEGF-A having a higher binding 
affinity to VEGFR-1, which can only be activated very weakly. Activation of VEGFR-1 has 
an uncertain effect on angiogenesis. Secondly, it has been reported that VEGF-A and PlGF 
heterodimerize with each other intracellularly and bind preferentially to VEGFR-1 instead of 
VEGFR-2. Due to the formation of heterodimers, the level of tumor cell secreted VEGF-A 
homodimers are decreased, thus reducing activation of VEGFR-2, and resulting in reduced 
angiogenesis and tumor growth rates. Conversely, when overexpressing PlGF in VEGF-A 
negative tumors, all the excess PlGF molecules are secreted as homodimers and have no 
chance to alter the number of host derived VEGF-A homodimers. Furthermore, numerous 
PlGF homodimers occupy more binding sites on VEGFR-1, thus saturating this receptor and 
pushing VEGF-A homodimers to bind to VEGFR-2, leading to enhanced angiogenesis, 
vascular permeability, and tumor growth signals (Paper I, Figure 4). 
5.2 SIGNALING MODULATION BY CROSS COMMUNICATION BETWEEN 
PROTEINS 
Data from paper I and paper II showed that PlGF-VEGFR-1 negatively modulated tumor 
angiogenesis when coexpressed with VEGF-A in the same cell. Based on previous research, 
PlGF may suppress tumor angiogenesis through the following mechanisms. The first 
mechanism may be due to activation of VEGFR-1 by PlGF. Knockout of Vegfr1 in mice 
causes excessive proliferation of embryonic ECs and vessel formation142. This hints that 
VEGFR-1 activation may be responsible for PlGF induced angiogenic inhibition. In paper II, 
we have further evidence of VEGFR-1 transduced negative signaling—if we block VEGFR-1 
downstream signal by genetic deletion of the tyrosine kinase domain, the inhibition of 
angiogenesis by PlGF overexpression became slightly weaker. The second mechanism may 
involve trapping VEGF-A on VEGFR-1. Knockout of Tyrosine kinase domain on Vegfr1 or 
Plgf did not result in hyper-vascularization shown in Vegfr1-/- mice143,138, suggesting that the 
binding sites of VEGFR-1 are sufficient for suppressing excessive angiogenesis without 
VEGFR-1 signaling capability. Meanwhile, it has been shown that the signal transduced by 
VEGF-A-VEGFR-1 binding is very weak even though the binding affinity of VEGF-A to 
VEGFR-1 is about 10 times of that of VEGF-A binding to VEGFR-2195. These data suggest 
the VEGFR-1 may serve as a decoy receptor for VEGF-A to reduce the promotion of 
angiogenesis. The final possible mechanism may be due to reduction of VEGF-A 
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homodimers. Dr. Eriksson reported that PlGF antagonized VEGF-induced angiogenesis and 
tumor growth by formation of PlGF-1/VEGF heterodimers196. Later, another publication 
verified this initial finding by Dr. Eriksson that overexpression of PlGF in tumor cells 
reduced secretion of VEGF-A homodimers. In addition to this confirmation, it was also seen 
that even if all PlGF was trapped in the cells by endoplasmic reticulum retention signal 
peptide preventing its secretion from cells, overexpression of PlGF still can inhibit tumor 
angiogenesis139. Taken together, this evidence shows that PlGF and VEGFR-1 can interact 
with VEGF-A and interfere with VEGF-A-VEGFR-2 induced angiogenesis at different levels, 
including affecting VEGF-A production, VEGF-A-VEGFR-2 binding and by negative 
angiogenic signaling from activation of VEGFR-1 upon ligand binding. 
Actually, there are other elegant signaling control systems capable of regulating angiogenesis. 
One such example is Angs and TIE receptors system(see 1.1.4.4). 
5.3 TARGETING TREATMENT 
In Paper III, VEGF neutralizing antibodies resulted in systemic vessel reduction in most of 
normal tissue and caused abnormal organ functions. To avoid such a wide range of side 
effects, a novel anti-angiogenic drug specially targeting the tumor vessels would be the best 
solution. To develop this kind of anti-angiogenic agent with strong specificity to the tumor, 
specific molecular signitures of the tumor vasculature need to be identified. These specific 
cell signatures have to be expressed on cell surface in order to guide the targeted anti-tumor 
agent to the tumor.  
To date, several cell surface molecules that are specifically overexpressed on tumor vessels 
have been found, such as, tumor endothelial marker 1 (TEM1), TEM5, TEM7 and TEM8197, 
198, 199. Notably, these cell markers highly or specially expressed in the tumor also participate 
actively in physiological process200, therefore, more details on the differences between 
physiological angiogenesis and pathological angiogenesis are still required.  
5.4 COMBINED TREATMENT OF MALIGNANT CANCER 
The side effects of anti-VEGF drugs are still challenging, however, the therapeutic outcomes 
obtained from anti-VEGF treatment have been validated in different models. We have seen 
the following benefits: (1) The immature vessels could not survive, leading to vessel 
regression201. (2) The tumor IFP was reduced and the delivery of other anti-tumor drug, 
macromolecules and oxygen was increased, therefore the efficiency of chemotherapy and 
radiotherapy was improved202, 203, 204. (3) The permeability of tumor vessels was reduced as 
well as the risk of tumor cell intravasation and distal metastasis49, 205, 206.  
Another way to enhance anti-tumor efficacy and reduce drug toxicity is to combine different 
therapies and minimize the dose of each drug. As mentioned above, the vessel modification 
by anti-VEGF treatment may increase the curative effect of conventional chemotherapeutics 
or radiotherapy. Our recent study has demonstrated that anti-angiogenic TKIs—such as 
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sunitinib (commercially named as Sutent, Pfizer) significantly improved tumor bearing mice 
survival by reducing chemotoxicity of cyclophosphamide (CTX) and carboplatin207. 
In another study, Dr. Bruns208 et al. combined DC101 with gemcitabine to treat pancreatic 
tumors and found increased cell death and decreased cell proliferation. One research added 
VEGF-TRAP to paclitaxel treatment and reduced ovarian tumor burden209. Zips and 
colleagues delayed the squamous carcinoma growth by combination of vatalanib (PTK787, 
Bayer Schering and Novartis) and radiotherapy210. Moreover, combination of anti-
hematoangiogenesis and anti-lymphangiogenesis agents showed better therapeutic outcomes 
in controlling tumor development and metastasis then a single anti-angiogenic approach211, 212. 
5.5 BIOMARKERS FOR TREATMENT OUTCOMES AND PROGNOSIS 
In clinical practice, we not only choose the better therapeutic regimen for the patients 
according to indications and contraindications, but also select treatment of patients by certain 
biomarkers that can did prediction of the therapeutic efficacy and prognosis. With some level 
of prediction, the treatment may result in very modest benefits and cause harmful side effects. 
A perfect biomarker should have the following features: (1) Sensitivity: its levels should 
change consistently together with the particular phenotype. (2) Feasibility: it should be easy 
to be detected the samples and the samples should be easy to obtain. The detection method 
should be quick, accurate and economical. (3) Specificity: it should be specific for a 
particular phenotype.  
It has been reported that the use of anti-PIGF on anti-VEGF drug resistant tumors led to 
inhibition of tumor growth213. This is in contrast to another study that did not show inhibition 
of angiogenesis and tumor growth in various tumors treated by PlGF blockade, except on a 
VEGFR-1 overexpression tumor214. Under these conditions, the expression level of VEGFR-
1 in a tumor may be a potential biomarker for anti-PlGF treatment. 
In paper II, mouse and human tumors with high PlGF expression were more sensitive to anti-
VEGF drug than the low PlGF expressing tumors. In this case, the expression level of PlGF 
in a tumor may serve as a potential biomarker for anti-VEGF treatment. 
Increasing evidences including our unpublished data, show that VEGF-B level in tumor is 
correlated with cancer metastasis and survival121, 215, thus VEGF-B can be a potent predictor 
for prognosis. 
Another candidate is FGF-2. Many researchers put efforts on validating the prognostic ability 
of FGF2 levels in urine or serum of cancer patients, however, the results are still ambiguous59, 
216, 217. Notably, FGF-2 has no signal peptide for secretion, subsequently, expression level of 
FGF-2 in cells does not necessarily correlate with the amount of FGF-2 outside the cells. Yet, 
cell damage and exocytosis has been confirmed as the potent alternative ways of releasing the 
growth factor to the ECM218.  
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Plenty of well-designed clinical studies are required to validate the potential of a new 
biomarker. Before that, we can do a preliminary assessment by checking and analyzing data 
from the clinical databases. 
5.6 VEGFR-3 PLAYS THE CRUCIAL ROLE IN LYMPHANIOGENESIS 
In paper IV, anti-VEGFR-3 treatment blocked FGF-2 stimulated lymphangiogenesis in 
mouse corneas by preventing LEC tip formation This means that VEGFR-3 activation is 
indispensable in lymphangiogenesis even though FGF-2 can independently induce LEC 
proliferation and migration in vitro. Upon reviewing the literature, more similar cases can be 
found. One of our recent paper uncovered that Tumor necrosis factor alpha (TNF-α) 
promoted lymphangiogenesis was blocked by VEGFR-3 neutralizing antibody which led to 
reduction in the number of the LEC tips219. Another study reported that hepatocyte growth 
factor (HGF) induced lymphangiogenesis was partly blocked by a soluble VEGFR-3220. All 
these results suggest that VEGFR-3 may play a crucial and irreplaceable role in inihibition of 
LEC tip formation during lymphangiogenesis under the control of many different factors. 
Certainly, there are still some questions that need to be answered. What is the active ligand 
for VEGFR-3 in FGF-2 induced angiogenesis? Is it possible that FGF-2 can directly activate 
VEGFR-3? Did FGF-2 lead to an increased expression of VEGFR-3 and VEGF-C or VEGF-
D? In future, we first can measure the expression level of VEGFR-3, VEGF-C and VEGF-D 
upon FGF-2 stimulation. Furthermore, we need to check which cell type is responsible for the 
production of VEGFR-3, VEGF-C and VEGF-D. The VEGF-C and VEGF-D blockade 
treatment can provide the information whether VEGF-C and VEGF-D are the only activator 
of VEGFR-3. 
5.7 ANIMAL MODELS IN PRECLINICAL STUDIES 
Because there are a few similarities in physiological and pathological states between humans 
and the other species, various types of animal models have been built up with the purpose of 
understanding the progression of human diseases. However, more and more translational 
studies revealed that the therapeutic effects seen from animal models could not be reproduced 
in clinical practice. We shall be careful when translating laboratory experimental data to 
clinical situations. Considering the differences between a group of experimental animals and 
a group of clinical patients, we can see why the difficulties exist. Firstly, genetic divergence 
of evolutionarily between creatures means that different species certainly do not react exactly 
the same way to different pathogenic situations or treatments. Secondly, there are many more 
individual variations among the humans than experimental animals, that are genetically 
identical and live under controlled environments. Nevertheless, animal models are still 
required for preclinical studies. Importantly, we should always set the appropriate control 
groups to minimize the interference and error. In addition, extra attentions should be paid to 
the “three R” principle when performing the animal experiment, reduce, refine and replace. 
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